Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors

Neurology India

Volumn 57, Issue 5, 2009, Pages 559-566

  Shukla, Bhaskar ^a   Agarwal, Shipra ^a   Suri, Vaishali ^a   Pathak, Pankaj ^a   Sharma, Mehar Chand ^a   Gupta, Deepak ^a   Sharma, Bhavani Shankar ^a   Suri, Ashish ^a   Halder, Ashutosh ^a   Sarkar, Chitra ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

1p 19q; Fluorescence in situ hybridization; Glioma; P53 protein

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; PROTEIN P53;

ADULT; ARTICLE; ASTROCYTE; ASTROCYTOMA; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; GROUPS BY AGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIXED TUMOR; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PEDIATRICS; PHENOTYPE; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 19; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 72849134874     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.57795     Document Type: Article

References (44)

1. Elia-Pasquet S, Provost D, Jaffré A, Loiseau H, Vital A, Kantor G, et al. Incidence of central nervous system tumors in Gironde France. Neuroepidemiology 2004;23:110-117
2. Kleihues P, Louis DN, Wiestler OD, Burger PC, Scheithauer BW. WHO grading of tumours of the central nervous system. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO classification of tumours of the central nervous system. 4th ed. Lyon: IARC; 2007. p. 10-11
3. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994;145:1175-1190
4. Fuller CE, Perry A. Molecular diagnostics in Central nervous system tumors. Adv Anat Pathol. 2005;12:180-194
5. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-1479
6. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636-645
7. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, et al. Molecular subtypes of anaplastic oligodendrogliomas: Implications for patient management at diagnosis. Clin Cancer Res 2001;7:839-845
8. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P. TP53 mutations in nonastrocytic human brain tumors. Cancer Res 1991;51:6202-6205
9. Hagel C, Laking G, Laas R, Scheil S, Jung R, Milde-Langosch K, et al. Demonstration of p53 protein and TP53 gene mutation in oligodendrogliomas. Eur J Cancer 1996;32:2242-2248
10. Jeon YK, Park K, Park CK, Paek SH, Jung HW, Park S. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: A clinicopathological study using fluorescence in situ hybridization. Neuropathol 2007;27:10-20.
11. Reifenberger J, Reifenberger G, Ichimura K, Schimdt EE, Wechsler W, Collins VP. Epidermal growth factor receptor expression in oligodendroglial tumors. Am J Pathol. 1996;149:29-35.
12. McLendon RE, Wikstrand CJ, Matthews MR, Al-Baradei R, Bigner SH, Bigner DD. Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. J Histochem Cytochem 2000;48:1103-1110
13. Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, et al. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 2004;63:314-322
14. Raghavan R, Balani J, Perry A, Margraf L, Vono MB, Cai DX, et al. Pediatric oligodendrogliomas: A study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropathol Exp Neurol 2003;62:530-537
15. Levin VA, Gutin PH, Leibel S. Neoplasms of the central nervous system, In: De Vita Jr VT. Hellman S, Rosenberg SA, editors. Cancer Principles and Practice of Oncology. 4th ed. Philadelphia: Lippincott, 1993. p. 1679-1737
16. Kelley TW, Tubbs RR, Prayson RA. Molecular diagnostic techniques for the clinical evaluation of gliomas. Diagn Mol Pathol 2005;14:1-8.
17. Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, et al. Allelic loss at Ip and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 1995;64:207-210
18. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, et al. Shared allelic losses on chromosomes 1 p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995;54:91-5.
19. Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997;56:1098-1104
20. Bigner SH, Rasheed BK, Wiltshire R, McLendon RE. Morphologic and molecular genetic aspects of ollgodendrogial neoplasms. Neuro Oncol 1999;1:52-60.
21. Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999;155:375-386
22. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22:3133-3138
23. Sasaki H, Zlatescu MC, Betensky RA, Johnk LB, Cutone AN, Cairncross JG, et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed lowgrade "oligodendroglioma." J Neuropathol Exp Neuro 2002;61:58-63.
24. Thiessen B, Maguire JA, McNeil K, Huntsman D, Martin MA, Horsman D. Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol 2003;64:271-278
25. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999;18:4144-4152
26. Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, et al. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol 2002;103:267-275
27. Gresner SM, Rieske P, Wozniak K, Piaskowski S, Jaskolski DJ, Skowronski W, et al. Gliomas: Association of histology and molecular genetic analysis of chromosomes 1p, 10q, and 19q. Acta Neurobiol Exp (Wars) 2007;67:103-112
28. Reddy KS. 1p/19q deletions by fluorescence in situ hybridization in gliomas. Cancer Genet Cytogenet 2008;184:77-86.
29. Herpers MJ, Budka H. Glial fibrillary acidic protein (GFAP) in oligodendroglial tumors: Gliofibrillary oligodendroglioma and transitional oligoastrocytoma as subtypes of oligodendrogliomas. Acta Neutopathol 1984;64:265-272
30. Jagadha V, Halliday WC, Becker LE. Glial fibrillary acidic protein (GFAP) in oligodendrogliomas: A reflection of transient GFAP expression by immature oligodendroglia. Can J Neurol Sci 1986;13:307-311
31. Sarkar C, Roy S, Tandon PN. Oligodendroglial tumors. An immunohistochemical and electron microscopic study. Cancer 1988;6:1862-1866
32. Kros JM, Van Eden CG, Stefanko SZ, Waayer-Van Batenburg M, van der Kwast TH. Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas. Cancer 1990;66:1204-1212
33. Kros JM, Stefanko SZ, de Jong AA, van Vroonhoven CC, van der Heul RO, van der Kwast TH. Ultrastructural and immunohistochemical segregation of gemistocytic subsets. Hum Pathol 1991;22:33-40.
34. Kreiger PA, Okada Y, Simon S, Rorke LB, Louis DN, Golden JA. Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol (Bert) 2005;109:387-392
35. von Deimling A, Eibl RH, Ohgaki H, Louis DN, von Ammon K, Petersen I, et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 1992;52:2987-2990
36. Nayak A, Ralte AM, Sharma MC, Singh VP, Mahapatra AK, Mehta VS, et al. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. Neurol India 2004;52:228-232
37. Kros JM, Godschalk JJ, Krishnadath KK, Van Eden CG. Expression of p53 in oligodendrogliomas. J Pathol 1993;171:285-290
38. Miettinen HE, Paunu N, Rantala I, Kalimo H, Paljärvi L, Helin H, et al. Cell cycle regulators (p21, p53, pRb) in oligodendrocytic tumors: A study by novel tumor microarray technique. J Neurooncol. 2001;55:29-37.
39. KorshunovA, Golanov A, Sycheva R. Immunohistochemical markers for prognosis of oligodendroglial neoplasms. J Neurooncol 2002;58:237-253 (Pubitemid 34830635)
40. Burger PC, Minn AY, Smith JS, Borell TJ, Jedlicka AE, Huntley BK, et al. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 2001;14:842-853
41. Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N, et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 2002;8:196-201.
42. Reifenberger G, Louis DN. Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 2003;62:111-126
43. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res 2004;64:6892-6899
44. Reis-Filho JS, Faoro LN, Carrilho C, Bleggi-Torres LF, Schmitt FC. Evaluation of cell proliferation, epidermal growth factor receptor, and bcl-2 immunoexpression as prognostic factors for patients with World Health Organization grade 2 oligodendroglioma. Cancer 2000;88:862-869